Skip to content

Double stranded DNA supported 3D CRISPR/Cas12a nanomachine for ultrasensitive biosensing of ctDNA in lung cancer

Double stranded DNA supported 3D CRISPR/Cas12a nanomachine for ultrasensitive biosensing of ctDNA in lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118972
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Research group:None
Control group:None

Sponsors

Chongqing General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with lung cancer by pathological or cytological examination (covering stages I-IV, regardless of specific pathological type); 2. Individuals confirmed through physical examination, imaging, and tumor marker tests to have no history of malignant tumors; 3. No serious organic diseases of major organs such as heart, liver, or kidneys; 4. Healthy individuals.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Patients with other malignant tumors (except lung cancer) or severe infectious diseases, or autoimmune diseases; 3. Patients who have recently (within 3 months) undergone hematopoietic stem cell transplantation, blood transfusion, or treatment with blood products (to avoid interference with ctDNA test results).

Design outcomes

Primary

MeasureTime frame
ctDNA testing performance;

Countries

China

Contacts

Public ContactLei Huxin

Chongqing General Hospital

506670964@qq.com+86 23 6339 0337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026